Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Epstein Barr virus-positive lymphoma, including the following subtypes:~  * Post-transplantation lymphoma~ * Burkitt's lymphoma~ * Hodgkin's lymphoma~ * T-/NK-cell lymphoma~* Unresponsive to, or relapsed after, at least 1 prior chemotherapy regimen~* Bidimensionally measurable disease by CT scan~* At least 1 lesion ≥ 1.5 cm in the greatest diameter~* Age 18 and over~* ECOG 0-2 OR~* Karnofsky 50-100%~* Life expectancy More than 3 months~* Hematopoietic~  * Absolute neutrophil count ≥ 1,000/mm\^3 (no growth factor support within the past 4 weeks)~ * Hemoglobin ≥ 9.0 g/dL~ * Platelet count ≥ 50,000/mm\^3 (no platelet transfusions within the past 4 weeks)~* Hepatic~  * Bilirubin ≤ 2.0 times upper limit of normal (ULN)~ * AST and ALT ≤ 2.5 times ULN (5 times ULN in patients with liver involvement)~ * No active hepatitis B or C~* Renal~  * Creatinine clearance ≥ 60 mL/min~ * Sodium \> 130 mmol/L~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* At least 4 weeks since prior immunotherapy~* At least 4 weeks since prior chemotherapy~* At least 4 weeks since prior radiotherapy~* More than 4 weeks since prior major surgery unless fully recovered~* Recovered from all prior therapy~* At least 4 weeks since prior investigational agents~Exclusion Criteria:~* primary or secondary CNS lymphoma or HIV-related lymphoma~* known brain metastases~* myocardial infarction within the past 6 months~* acute ischemia or new conduction system abnormalities by electrocardiogram~* symptomatic congestive heart failure~* unstable angina pectoris~* cardiac arrhythmia~* hospitalized~* pregnant or nursing~* other uncontrolled illness~* ongoing or active systemic infection~* psychiatric illness or social situation that would preclude study compliance~* history of allergic reaction attributable to compounds of similar chemical or biological composition to study drugs~* sensitivity to boron, mannitol, bortezomib, or ganciclovir~* concurrent corticosteroids (≥ 10 mg of prednisone or equivalent)~* concurrent radiotherapy~* other concurrent anticancer therapy~* other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib + ganciclovir (Type: EXPERIMENTAL): Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).